|
Market Closed -
OTC Markets
11:53:32 2026-07-02 EDT
|
5-day change | 1st Jan Change | ||
| 1.690 USD | +0.90% |
|
-.--% | +14.19% |
| 07-02 | Hanmi Pharmaceutical Closes Acquisition of Aptose Biosciences | MT |
| 06-29 | Hanmi Pharm. Co., Ltd. completed the acquisition of remaining 80.07% stake in Aptose Biosciences Inc.. | CI |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
EBT: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 (USD) | 2018 (USD) | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Net Income | -65.35M | -41.82M | -51.21M | -25.43M | -25.47M | |||||
D&A | 622K | 528K | 466K | 404K | 22K | |||||
EBT | -65.35M | -41.82M | -51.21M | -25.43M | -25.47M | |||||
CAPEX | -212K | -24K | -29K | -5K | - | |||||
Interest Expense | - | - | - | -207K | -843K | |||||
Total Assets | 82.52M | 51.03M | 12.99M | 10.13M | 10.01M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 (USD) | 2018 (USD) | 2019 (USD) | 2020 (USD) | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|---|---|---|---|---|
EBT | -65.35M | -41.82M | -51.21M | -25.43M | -25.47M | |||||
Net Income | -65.35M | -41.82M | -51.21M | -25.43M | -25.47M | |||||
CAPEX | -212K | -24K | -29K | -5K | - | |||||
D&A | 622K | 528K | 466K | 404K | 22K | |||||
Interest Expense | - | - | - | -207K | -843K | |||||
Total Assets | 82.52M | 51.03M | 12.99M | 10.13M | 10.01M |
- Stock Market
- Stocks
- APS Stock
- APTO Stock
- Financials Aptose Biosciences Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
